125. IVC Ultrasound and Volume Responsiveness

Should this patient get more fluid? It comes up on nearly every ICU shift, and the IVC is usually the first thing we scan to answer it. In this Pulm PEEPs Pearls episode, Furf and Monty cover how to get a reliable IVC view, how to read it in intubated and spontaneously breathing patients, the cutoffs worth knowing, what the data actually show, and the pitfalls that make the IVC mislead us.

Key Learning Points

Volume Responsiveness vs. Volume Status

“Volume status,” “volume depleted” and “fluid responsive” get used interchangeably on rounds, but they are not the same thing. Fluid responsiveness is a physiologic definition: a patient is fluid responsive if a fluid bolus (usually 250 to 500 mL) increases stroke volume or cardiac output by at least 10 to 15 percent. In Frank-Starling terms, you are asking whether both ventricles are still on the steep part of the curve.

Only about half of hemodynamically unstable ICU patients are fluid responsive. This has been shown again and again, going back to the classic Michard and Teboul review. If we bolus everyone who is hypotensive, roughly half get the downsides of fluid (edema, worse oxygenation, organ congestion) with none of the upside.

Responsive does not necessarily mean needs fluid. Most healthy people are fluid responsive. A patient can even be fluid responsive and volume overloaded at the same time. Responsiveness only tells you the heart can use more preload, so the decision always sits inside the clinical picture:

  • Is there hypoperfusion?
  • Is there reason to think low cardiac output is the problem?
  • Will the patient tolerate more fluid, especially from a lung standpoint?

Why Would the IVC Tell Us Anything?

The IVC is a thin-walled, compliant vessel sitting between the abdomen and the right atrium. Its size reflects the balance between right atrial pressure on one side and intra-abdominal pressure on the other. Breathing changes the pressures around it, and how the IVC responds depends entirely on whether the patient is breathing on their own or receiving positive pressure.

  • Spontaneously breathing: inspiration makes intrathoracic pressure negative, blood is pulled into the chest, and the IVC gets smaller. This is collapsibility.
  • Passively ventilated: each positive-pressure breath raises intrathoracic and right atrial pressure, impeding venous return, so the IVC gets bigger on inspiration. This is distensibility.

The theory: a patient on the flat part of the Frank-Starling curve has a high right atrial pressure and a full, stiff IVC that barely moves. A patient on the steep part has a lower right atrial pressure and a more compliant IVC that swings with each breath. Lots of respiratory variation suggests fluid responsiveness; very little suggests fluid will not help.

Quick bedside trick: take a deep breath yourself. Your chest expands, your diaphragm drops, intrathoracic pressure falls and your IVC empties into the right atrium. Positive pressure is the reverse.

Getting the Image

You cannot do this well without practice, so scan your patients routinely, not only when the stakes are high.

  • Probe and preset: phased array or curvilinear probe, with the abdominal or cardiac preset.
  • Position: patient supine. Head position matters a little, so keep it consistent if you plan to compare scans over time.
  • Find the IVC: start subxiphoid, slightly to the patient’s right, with the marker toward the head in a longitudinal (sagittal) plane. Many people start with a subcostal four-chamber view of the heart, then rotate to longitudinal to bring the IVC to the center of the screen. You want to see the IVC running through the liver into the right atrium.
  • Prove it’s the IVC: everyone has measured the aorta at some point. The IVC enters the right atrium and receives a hepatic vein. The aorta is thick-walled, pulsatile, deeper and to the patient’s left, and gives off the celiac and SMA rather than receiving hepatic veins. Fan over to find the aorta, or rotate to a transverse view to see both side by side. Color or pulsed-wave Doppler can help if you are unsure.
  • Measure in the right spot: 1 to 2 cm caudal to the hepatic vein junction (about 2 to 3 cm from the cavoatrial junction), perpendicular to the long axis of the vessel, inner wall to inner wall.
  • Capture the max and min: drop an M-mode line through that spot and record over several breaths. Many ultrasound machines have a built-in calculation package that will compute the index for you once you mark the maximum and minimum.
  • Watch for translation: the IVC moves with the diaphragm and can slide in and out of the M-mode line, which can look like collapse. Watch the B-mode clip, or measure in B-mode at a fixed anatomic landmark.
  • Avoid the cylinder effect: the IVC is a tube. A slice through its edge underestimates the diameter and can exaggerate collapse. Fan through the vessel and measure at its widest point.
  • No subcostal window? Post-op abdomen, body habitus and bowel gas are common in the ICU. Use the right lateral transhepatic coronal view at the mid-axillary line, using the liver as your window (the same view used in VExUS). Measurements are not perfectly interchangeable with the subcostal view, so use the same view each time you trend. If you cannot get confident landmarks, this may not be the right test for this patient.
Ivc 1 technique

The Intubated Patient: Distensibility

The IVC works best in mechanically ventilated patients because we control the breath. Two classic indices, both from 2004 and both in French septic shock patients, give us the numbers most people quote:

IndexFormulaCutoff suggesting responseStudy
Distensibility index (dIVC)(Dmax − Dmin) / Dmin> 18%Barbier 2004, n = 23: sensitivity and specificity ~90%
ΔIVC(Dmax − Dmin) / Dmean> 12%Feissel 2004, n = 39: PPV 93%, NPV 92%

Match the formula to the cutoff. Mixing them up is one of the most common errors. The easy way to remember it: 18 percent if you divide by the minimum, 12 percent if you divide by the mean. If your machine calculates the index, check which formula it uses.

Know the conditions these were validated in. Patients were fully passive on the ventilator, in volume control, with tidal volumes of about 8 to 10 mL/kg. In today’s ICU, with lung-protective ventilation at 6 mL/kg and patients often triggering breaths, those conditions frequently do not apply. Choose your patient carefully: passive on the vent, with an adequate tidal volume.

The Spontaneously Breathing Patient: Collapsibility

In the ED or on the floor, we are looking at collapsibility (the caval index): (Dmax − Dmin) / Dmax. Here the story gets messier. We do not control the rate or the effort, and a small shallow breath versus a big deep sniff gives very different collapsibility in the same patient at the same volume status. Many septic patients are also breathing hard, which changes intrathoracic dynamics considerably.

Three studies are worth knowing:

  • Muller 2012 (n = 40, acute circulatory failure): collapsibility > 40% had a sensitivity of 70% and specificity of 80%. A value below 40% did not rule out fluid responsiveness.
  • Airapetian 2015 (n = 59): overall performance was poor (AUC 0.62), but collapsibility > 42% was very specific (97%) with a sensitivity of only 31%.
  • Preau 2017 (n = 90, septic, non-intubated): standardizing the breath, a deep inspiration followed by passive exhalation, collapsibility ≥ 48% had a sensitivity of 84%, specificity of 90% and AUC of 0.89.

The practical takeaway: near-complete collapse, over 40 to 50 percent, especially with a standardized deep breath, makes fluid responsiveness more likely. A big number means something; a small number does not tell you much. And anyone can collapse their IVC if they are breathing hard enough, so in true respiratory distress this test is of little use.

What About Just the Size of the IVC?

“The IVC is flat, give fluid” is still heard on rounds, but the static diameter answers a different question. It comes from the echo world, where it is used to estimate right atrial pressure in spontaneously breathing patients, many of them outpatients. Per the American Society of Echocardiography right heart guidelines (Rudski 2010):

IVC diameter and sniff collapseEstimated RAP (mmHg)
≤ 2.1 cm and > 50% collapse~3 (0–5)
Everything in between~8
> 2.1 cm and < 50% collapse~15 (10–20)

Estimating right atrial pressure is not predicting fluid responsiveness. Decades of ICU data show that static pressures, even a directly measured CVP, are poor predictors of fluid responsiveness. This takes us right back to the difference between volume status and volume responsiveness.

The static IVC is most useful at the extremes. A tiny, nearly virtual IVC (under about 1 cm) in a hypotensive patient makes fluid responsiveness more likely. A large, non-collapsing IVC should make you pause and think about the right heart, tamponade or volume overload. As with our FeNO episode, the extremes are informative and the middle is gray.

Ivc 2 interpretation

What Do the Data Show?

The IVC is a modest predictor of fluid responsiveness, with wide variation across studies. Performance is best in passive ventilated patients and weakest with spontaneous breathing:

StudyPopulationIndex and cutoffPerformance
Barbier 200423 ventilated, septicdIVC > 18%Sens 90%, spec 90%
Feissel 200439 ventilated, septic shockΔIVC > 12%PPV 93%, NPV 92%
Vignon 2017540 ventilated, multicenterΔIVC ≥ 8%Sens 55%, spec 70%
Muller 201240 spontaneously breathingcIVC > 40%Sens 70%, spec 80%, AUC 0.77
Airapetian 201559 spontaneously breathingcIVC > 42%Sens 31%, spec 97%, AUC 0.62
Preau 201790 spontaneously breathing, deep breathcIVC ≥ 48%Sens 84%, spec 90%, AUC 0.89
Orso (meta-analysis)20 studiesPooledSens 71%, spec 75%, AUC 0.71
Kim 2021 (meta-analysis)30 studies, 1,719 patientsPooledSens 75%, spec 83%, AUC 0.86

Note how much the large multicenter Vignon cohort pulls the ventilated numbers down compared with the small original studies. The meta-analyses are mixed and very heterogeneous: Orso and colleagues concluded the IVC is not a reliable predictor on its own, while Kim and colleagues found better pooled accuracy. Both pointed to huge variation in patient populations, formulas, cutoffs and how responsiveness was defined.

Putting it together: the IVC is fast, noninvasive and repeatable, and it is a useful piece of the puzzle. It should never be the only thing driving the decision to give fluid. When it really matters, a passive leg raise paired with a measure of cardiac output performs far better (pooled AUC ~0.95, Monnet 2016). We will cover LVOT VTI, pulse pressure variation and VExUS in future episodes.

Ivc 3 evidence

Pitfalls: When the IVC Can Mislead You

The patients we most want to answer this question for are often the ones in whom the IVC is least reliable.

On the ventilator

  • Spontaneous effort: patient-triggered breaths mix collapse and distension, and the cutoffs no longer apply.
  • Low tidal volume: at 6 mL/kg, the change in intrathoracic pressure may be too small to move the IVC, causing false negatives.
  • High PEEP: raises right atrial pressure on its own, distending the IVC and blunting variation.

In the patient

  • Raised intra-abdominal pressure: abdominal compartment syndrome, tense ascites, bowel distension or a recent abdominal surgery can compress the IVC, so a small, collapsible IVC may not mean responsive.
  • Right heart disease: RV failure, severe tricuspid regurgitation, pulmonary hypertension, PE and tamponade all give a plethoric IVC independent of volume. In tamponade or massive PE, of course, that plethoric IVC is important diagnostic information in its own right.
  • Vigorous breathing: in asthma, COPD exacerbations or any respiratory distress, forceful inspiration can collapse even a full IVC, and active exhalation distorts the measurement.

In the technique

  • Wrong vessel: the aorta is pulsatile, thick-walled and to the left. Confirm hepatic vein inflow.
  • Cylinder effect and translation: off-center slices and the IVC sliding out of the M-mode line both fake collapse.
  • Mismatched formula and cutoff: 18% goes with dividing by the minimum, 12% with dividing by the mean.

And remember: responsive does not mean needs fluid. Check tolerance too, with lung ultrasound and VExUS for venous congestion.

Ivc 4 pitfalls

The Five Pulm PEEPs Pearls

  1. Fluid responsive doesn’t mean fluid needed. Only about half of unstable ICU patients respond to fluid, and responsiveness is only one part of the decision. Always ask whether the patient needs, and can tolerate, more preload.
  2. Know the breathing pattern and the formula. Passive and intubated: distensibility over 18% (divide by the minimum) or over 12% (divide by the mean). Spontaneously breathing: collapsibility over 40 to 50% suggests response, especially with a standardized deep breath.
  3. The extremes are your friends. A tiny, fully collapsing IVC makes responsiveness more likely. A big, plethoric IVC should make you think about the right heart, tamponade or volume overload. A non-collapsing IVC in a spontaneously breathing patient doesn’t rule out response.
  4. Respect the pitfalls. Spontaneous effort on the vent, low tidal volumes, high PEEP, intra-abdominal hypertension and right heart disease all undermine the IVC, and they are common in our sickest patients. Prove it’s the IVC, and watch for the cylinder effect and translation.
  5. When it matters, go dynamic. A passive leg raise with LVOT VTI outperforms the IVC and works in many of the patients where the IVC fails.
Ivc 5 pearls

Scan carefully, interpret in context, and as always, keep breathing!

References and Further Reading

  • Michard F, Teboul JL. “Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence.” Chest. 2002;121(6):2000–2008.
  • Barbier C, Loubières Y, Schmit C, et al. “Respiratory changes in inferior vena cava diameter are helpful in predicting fluid responsiveness in ventilated septic patients.” Intensive Care Med. 2004;30(9):1740–1746.
  • Feissel M, Michard F, Faller JP, Teboul JL. “The respiratory variation in inferior vena cava diameter as a guide to fluid therapy.” Intensive Care Med. 2004;30(9):1834–1837.
  • Muller L, Bobbia X, Toumi M, et al. “Respiratory variations of inferior vena cava diameter to predict fluid responsiveness in spontaneously breathing patients with acute circulatory failure: need for a cautious use.” Crit Care. 2012;16(5):R188.
  • Airapetian N, Maizel J, Alyamani O, et al. “Does inferior vena cava respiratory variability predict fluid responsiveness in spontaneously breathing patients?” Crit Care. 2015;19:400.
  • Preau S, Bortolotti P, Colling D, et al. “Diagnostic accuracy of the inferior vena cava collapsibility to predict fluid responsiveness in spontaneously breathing patients with sepsis and acute circulatory failure.” Crit Care Med. 2017;45(3):e290–e297.
  • Vignon P, Repessé X, Bégot E, et al. “Comparison of echocardiographic indices used to predict fluid responsiveness in ventilated patients.” Am J Respir Crit Care Med. 2017;195(8):1022–1032.
  • Orso D, Paoli I, Piani T, et al. “Accuracy of ultrasonographic measurements of inferior vena cava to determine fluid responsiveness: a systematic review and meta-analysis.” J Intensive Care Med. 2020;35(4):354–363.
  • Kim DW, Chung S, Kang WS, Kim J. “Diagnostic accuracy of ultrasonographic respiratory variation in the inferior vena cava, subclavian vein, internal jugular vein, and femoral vein diameter to predict fluid responsiveness: a systematic review and meta-analysis.” Diagnostics (Basel). 2021;12(1):49.
  • Rudski LG, Lai WW, Afilalo J, et al. “Guidelines for the echocardiographic assessment of the right heart in adults.” J Am Soc Echocardiogr. 2010;23(7):685–713.
  • Monnet X, Marik P, Teboul JL. “Passive leg raising for predicting fluid responsiveness: a systematic review and meta-analysis.” Intensive Care Med. 2016;42(12):1935–1947.

124. Fractional Exhaled Nitric Oxide (FeNO)

PPP Cover Images

Furf and Monty are back! For our first episode back in the studio, we’re returning with a Pulm PEEPs Pearls episode on a test that is showing up more and more in pulmonary clinic: fractional exhaled nitric oxide, or FeNO. Using a patient with asthma-like symptoms and a FeNO that lands right in the middle, Furf and Monty walk through what the test measures, how to interpret the number, what can push it up or down, and how to use it for both diagnosis and monitoring.

Contributors

This episode was prepared with research by Pulm PEEPs Associate Editor George Doumat.

Key Learning Points

The Case

A 28-year-old accountant presents with six months of episodic cough and wheeze. Her spirometry is normal with no bronchodilator response, but her FeNO comes back at 42 ppb. Does she have asthma?

The honest answer: maybe. FeNO is not a yes/no asthma test, and a single number has to be interpreted in clinical context.

What Is FeNO Measuring?

FeNO measures the concentration of nitric oxide in exhaled breath. In type 2 airway inflammation, Th2 cells and ILC2s release IL-4 and IL-13, which signal through the IL-4Rα/IL-13Rα1 receptor (JAK1 → STAT6) to induce iNOS (NOS2) in airway epithelial cells. iNOS converts L-arginine to nitric oxide, which diffuses into the airway lumen and is measured by the analyzer at a standardized exhalation flow of 50 mL/s, reported in parts per billion (ppb).

Bottom line: FeNO gives us a window into type 2 (eosinophilic, allergic-pathway) airway inflammation at the cellular level, something spirometry can’t tell us.

Feno diagram

Three Tests, Three Questions

Each airway test answers a different question, and all three can feed into an asthma diagnosis:

TestQuestion It Answers
SpirometryIs there airflow obstruction?
Methacholine challengeIs there airway hyperresponsiveness?
FeNOIs there type 2 airway inflammation?

These tests don’t always point in the same direction. A patient can have normal spirometry and a negative methacholine challenge but still have an elevated FeNO if there is active eosinophilic inflammation, and the reverse can happen too.

Airway tests

Interpreting the Number

Feno interpretation vertical

The ATS thresholds for adults are easy to remember because they move in 25s:

FeNO (adults)CategoryWhat It Suggests
< 25 ppbLowType 2 inflammation unlikely; steroid response less likely; consider other diagnoses
25–50 ppbIntermediateType 2 inflammation possible; interpret in clinical context; repeat or trend over time
> 50 ppbHighType 2 inflammation likely; steroid response likely; supports an asthma diagnosis in the right context

The extremes are your friends. A value below 25 ppb or above 50 ppb is far more actionable than one in the intermediate range. In the 25–50 zone, we have to do some doctoring.

Children are different: in children under 12, cutoffs are < 20 ppb (low), 20–35 ppb (intermediate), and > 35 ppb (high). Don’t carry adult thresholds over.

What Moves the Number

Before interpreting a value, think about what might be confounding it.

Lowers FeNO:

  • Current smoking. A “normal” value in a smoker can be falsely reassuring.
  • Inhaled or oral corticosteroids, which suppress the type 2 signal.
  • Biologics, especially dupilumab (which blocks IL-4Rα).
  • Recent spirometry or exercise.
  • Acute bronchoconstriction. A patient in a severe flare can’t exhale fully, so the value may be artificially low. This is not a test for the middle of an exacerbation.

Raises FeNO:

  • Atopy and allergic rhinitis, or ongoing allergen exposure
  • Viral respiratory infection
  • Nitrate-rich foods (leafy greens, beets)
  • Male sex and taller height (modest effect)

Testing tips: measure FeNO before spirometry, and have patients avoid food and drink for 1 hour beforehand.

Back to Our Patient

Our patient’s FeNO of 42 ppb is intermediate. It isn’t a diagnosis, but this is exactly the scenario where FeNO earns its keep: she has asthma-like symptoms and the usual physiologic testing hasn’t given us an answer. An elevated value adds evidence that a type 2 eosinophilic process may be present in her airways.

Two important caveats:

  • A positive FeNO supports the phenotype, but doesn’t close the case. Current asthma guidelines incorporate FeNO into diagnosis and monitoring, but it belongs inside the diagnostic pathway as one more piece of evidence. Patients are sometimes labeled with asthma based on a single intermediate FeNO, only to have a normal methacholine challenge and an entirely different explanation for their symptoms.
  • A low FeNO doesn’t rule out asthma. Non-eosinophilic and neutrophilic asthma phenotypes exist, and FeNO isn’t designed to detect them.

Using FeNO to Monitor Asthma

Once a patient carries an asthma diagnosis, FeNO can become actionable.

Persistent symptoms + persistently high FeNO: There is still a type 2 inflammatory signal, but don’t reflexively escalate inhaled corticosteroids. First ask why the signal is still there:

  • Is the patient actually taking the ICS (adherence)?
  • Are they using the inhaler correctly (technique and delivery)?
  • Is there ongoing allergen exposure?
  • Is the current anti-inflammatory dose simply inadequate?

Sometimes a high FeNO is telling you about adherence or delivery, not that the prescription isn’t strong enough.

Persistent symptoms + low FeNO: Especially if blood eosinophils are also low, pause before adding more ICS. Consider a different asthma phenotype, an alternative diagnosis, or another contributor to the symptoms. FeNO can keep us from treating every symptom as though it means more steroid.

The evidence: A 2023 systematic review and meta-analysis of 12 RCTs in adults found that FeNO-guided treatment probably reduces exacerbations compared with symptom-guided treatment, with less clear effects on quality of life, lung function, and other outcomes.

Follow the trend, not the cutoff. Once you’re following a patient over time, they become their own control, and the trajectory matters more than whether a value crosses from 48 to 52 ppb. A meaningful change is generally considered:

  • > 20% if the baseline is > 50 ppb
  • > 10 ppb if the baseline is < 50 ppb

An elevated FeNO that falls meaningfully after starting ICS supports that you’ve actually changed the airway inflammation.

Beyond Asthma: Chronic Cough

FeNO can also help in the workup of chronic cough. A patient with chronic cough, an elevated FeNO, normal spirometry, and a negative methacholine challenge may have non-asthmatic eosinophilic bronchitis, which can respond to inhaled corticosteroids. Systematically working through and crossing off treatable causes is also what allows us to confidently name refractory chronic cough. For more, check out our episode Pulm PEEPs & Irish Thoracic Society: Understanding Refractory Chronic Cough.

The Four Pulm PEEPs Pearls

Feno pearls
  1. Inflammation, not obstruction: FeNO measures type 2 eosinophilic airway inflammation, not airflow obstruction. That’s why it complements spirometry and methacholine challenge rather than replacing either one.
  2. The extremes are your friends: Above 50 ppb supports type 2 inflammation and makes steroid responsiveness more likely in the right clinical context. Below 25 ppb argues against active eosinophilic disease. From 25 to 50 ppb, context matters.
  3. Supports, but doesn’t diagnose: FeNO can support an asthma diagnosis, but it doesn’t make the diagnosis by itself, and a low FeNO does not rule out asthma.
  4. Persistently high? Ask why: Before simply escalating therapy, check adherence, inhaler technique, allergen exposure, and whether anti-inflammatory treatment is adequate. When following someone over time, the trend may be more informative than any single number.

Remember: we’re treating the patient, not the FeNO number.

References and Further Reading

Dweik, Raed A et al. “An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.” American journal of respiratory and critical care medicine vol. 184,5 (2011): 602-15. doi:10.1164/rccm.9120-11ST

American Thoracic Society; European Respiratory Society. “ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005.” American journal of respiratory and critical care medicine vol. 171,8 (2005): 912-30. doi:10.1164/rccm.200406-710ST

Korevaar, Daniël A et al. “Effectiveness of FeNO-guided treatment in adult asthma patients: A systematic review and meta-analysis.” Clinical and experimental allergy vol. 53,8 (2023): 798-808. doi:10.1111/cea.14359

Petsky, Helen L et al. “Exhaled nitric oxide levels to guide treatment for adults with asthma.” The Cochrane database of systematic reviews vol. 9,9 CD011440. 1 Sep. 2016, doi:10.1002/14651858.CD011440.pub2

Louis, Renaud et al. “European Respiratory Society guidelines for the diagnosis of asthma in adults.” The European respiratory journal vol. 60,3 2101585. 15 Sep. 2022, doi:10.1183/13993003.01585-2021

Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI). “2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.” The Journal of allergy and clinical immunology vol. 146,6 (2020): 1217-1270. doi:10.1016/j.jaci.2020.10.003

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated annually. Available at ginasthma.org.

122. Pulm PEEPs Pearls: Steroids in Sepsis

PPP Cover Images (1)

Today we have another Pulm PEEPs Pearls episode about a core critical care topic. Furf and Monty will be giving a high level overview of the use of steroids in sepsis including a review of the relevant literature and recent guidelines, and pragmatic bedside points.

This episode was prepared with research by Pulm PEEPs Associate Editor George Doumat.

Dustin Latimer, another Pulm PEEPs Associate Editor, assisted with audio and video editing.

Why Steroids in Sepsis?

Steroids do not treat the infection — antimicrobials are always first and remain the cornerstone. The goal is addressing critical illness–related corticosteroid insufficiency (CIRCI), where cortisol production cannot keep up with the overwhelming inflammatory demand of septic shock.

Hydrocortisone helps in two main ways:

  • Blunts the dysregulated inflammatory response — tempers the excessive vasodilation and febrile response that drive harm beyond the infection itself.
  • Restores vascular sensitivity to catecholamines — sepsis downregulates adrenergic receptors; steroids turn that responsiveness back on.

Clinical takeaway: The first thing you notice is vasopressor weaning (or a bend in the escalation curve) — not a rapid improvement in fever or white count.

Caveat: These trials predate modern sepsis phenotyping. None distinguish hyperinflammatory vs. hypoinflammatory responders — they treat all comers.

The Evidence: Four Landmark Trials

Every IM resident and critical care fellow will eventually journal-club these four. The most consistent signal across all of them is faster shock reversal and reduced vasopressor use; the mortality question remains unsettled.

Trial (Year)NRegimenKey Finding
Annane (2002)~300Hydrocortisone + fludrocortisoneMortality benefit in ACTH non-responders; criticized methodology and messy cortisol-response testing; not cleanly replicated.
CORTICUS (2008)~500Hydrocortisone aloneFaster shock reversal but no mortality benefit, regardless of cortisol responsiveness. Raised (later allayed) superinfection concern. Cornerstone for abandoning routine cort-stim testing.
ADRENAL (2018)~3,800Hydrocortisone aloneFaster vasopressor weaning; no 90-day mortality benefit.
APROCCHSS (2018)~1,200Hydrocortisone + fludrocortisoneMortality benefit at 90 days.

Bottom line: Faster shock reversal is consistent. Mortality benefit appears in 2 of 4 trials (both used fludrocortisone) but not the others. A 2026 meta-analysis showed benefit for hydrocortisone + fludrocortisone vs. placebo, but

not for hydrocortisone + fludrocortisone vs. hydrocortisone alone — suggesting hydrocortisone drives the main effect.

Who Gets Steroids, and When?

  • 2021 Surviving Sepsis: Consider steroids for norepinephrine or epinephrine ≥ 0.25 mcg/kg/min for ≥ 4 hours despite adequate resuscitation — a reasonable bedside trigger.
  • Early 2026 update: Moved away from a specific numeric trigger — consider steroids when a septic patient is not responding well to vasopressors or has escalating requirements. Make a clinical decision. (Quality of evidence: low to moderate.)
  • Go faster than the threshold when: Known/suspected adrenal insufficiency or home steroids, or florid pressor-requiring shock on arrival.

A practical escalation sequence: escalating norepinephrine → add vasopressin (per VASST) → then add steroids if requirements keep climbing.

Do NOT wait for an ACTH stimulation test. It does not reliably predict who responds and only delays treatment. Sepsis is an elevated-cortisol state but can dissociate ACTH and cortisol, and cortisol-binding globulin is depleted — the test is too messy to guide care.

What to Give: The Regimen

  • Standard dose: Hydrocortisone 200 mg/day, typically 50 mg IV Q6H. (Original trials often used continuous infusions, rarely used in the U.S.) Some start with a 100 mg bolus to gain control.
  • Higher dose: If chronically on steroids / adrenally insufficient, consider ~300 mg/day (e.g., 100 mg Q8H).
  • Fludrocortisone: Unsettled. The two mortality-benefit trials added it (50 mcg PO/NG/OG daily), but hydrocortisone already has mineralocorticoid activity and meta-analyses don’t show added benefit over hydrocortisone alone. Most clinicians omit it — adding it is reasonable and safe, just be honest about the uncertainty.

Duration & Tapering

  • Typical course: ~7 days is most common. Trial practices varied (ADRENAL ~7 days; VANISH used a taper after 6 days; some continue until pressors are off).
  • No taper needed. You do not need to taper for adrenal insufficiency after a short course — just stop. If pressors dramatically rebound, you can restart, but most patients have gained the benefit they’ll get by day 7.

Pitfalls & Safety

  • Hyperglycemia: Expected and must be managed (monitor closely; insulin drip if needed). No signal for major DKA / severe complications in the trials.
  • Superinfection / fungal infection: The most-quoted concern, but the overall literature does not show a convincing, statistically significant increase. Be disciplined about stopping on schedule.
  • Muscle weakness: Steroids can worsen critical illness myopathy; a short 7-day course likely has limited effect, but be aware.
  • Other: GI bleeding (follow general PPI prophylaxis guidance) and sodium disturbances (watch for hyper-/hyponatremia).

Two things we know: (1) steroids shorten duration of vasopressor support, and (2) they are relatively safe in sepsis. Whether they improve mortality — and in whom — remains open.

The Five Pulm PEEPs Pearls

  1. Mechanism: Steroids restore catecholamine vascular sensitivity and blunt dysregulated inflammation. The clinical target is vasopressor weaning, not infection treatment.
  2. Evidence: Faster shock reversal is the most consistent finding. Mortality benefit is seen in 2 of 4 trials but not the others — still controversial. Some patients likely benefit; we don’t yet know who.
  3. Trigger: A practical 2021 threshold is levo/epi ≥ 0.25 mcg/kg/min for ≥ 4 hours. Newer guidance drops the strict number — make a clinical decision based on poor pressor response or escalation.
  4. Dose: Hydrocortisone 200 mg/day (e.g., 50 mg Q6H). Adding fludrocortisone mirrors two trials, but meta-analyses find no benefit over hydrocortisone alone.
  5. Safety: Steroids appear safe in sepsis. Monitor and treat hyperglycemia; no marked increase in superinfection.

Annane, Djillali et al. “Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.” JAMA vol. 288,7 (2002): 862-71. doi:10.1001/jama.288.7.862

Sprung, Charles L et al. “Hydrocortisone therapy for patients with septic shock.” The New England journal of medicine vol. 358,2 (2008): 111-24. doi:10.1056/NEJMoa071366

Venkatesh, Balasubramanian et al. “Adjunctive Glucocorticoid Therapy in Patients with Septic Shock.” The New England journal of medicine vol. 378,9 (2018): 797-808. doi:10.1056/NEJMoa1705835

Annane, Djillali et al. “Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.” The New England journal of medicine vol. 378,9 (2018): 809-818. doi:10.1056/NEJMoa1705716

Sun, Alin et al. “Correction: Hydrocortisone combined with fludrocortisone for treatment of adults with septic shock: an updated meta-analysis and systematic review.” Frontiers in medicine vol. 13 1811616. 2 Mar. 2026, doi:10.3389/fmed.2026.1811616

Prescott, Hallie C et al. “Executive Summary: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026.” Critical care medicine vol. 54,4 (2026): 715-724. doi:10.1097/CCM.0000000000007089

118. Pulm PEEPs Pearls: Methacholine Challenge

PPP Cover Images

Furf and Monty are back with another Pulm PEEPs Pearls episode. The topic of today’s discussion is an often discussed, but often misunderstood, test; the methacholine challenge. They’ll review when to utilize this test, how it should be performed, and the appropriate interpretation.

This episode was prepared with research by Pulm PEEPs Associate Editor George Doumat.

Dustin Latimer, another Pulm PEEPs Associate Editor, assisted with audio and video editing.

What the Test Measures

  • Methacholine challenge is a direct bronchial provocation test of airway hyperresponsiveness (AHR), a core physiologic feature of asthma.
  • Anyone will bronchoconstrict at high enough concentrations — the test looks for an abnormal threshold.
  • The key endpoint is the PC20: the methacholine concentration causing a 20% fall in FEV1.
    • Abnormal in adults: PC20 ≤ 8–16 mg/mL

Test Performance

  • Meta-analyses: pooled sensitivity ~60%, specificity ~90%.
  • Real-world cohorts: sensitivity 55–62%, specificity 56–100% (varies by population, protocol, and threshold used).
  • Not a standalone yes/no test — best used as part of a broader diagnostic pathway.

Where It Fits in the Asthma Workup

The test belongs in a stepwise approach:

  1. Step 1: Spirometry + bronchodilator response
  2. Step 2: Add FeNO and/or peak flow variability (if available)
  3. Step 3: If the picture is still unclear → methacholine challenge

It is most useful for symptomatic patients with normal spirometry and no bronchodilator reversibility. Given its cost, mild risk, and discomfort, it should not be a first-line test — most asthma diagnoses do not require it.

Technique and Medication Prep

Technique

  • ERS guidelines favor tidal breathing over deep inspiratory maneuvers.
  • Deep breaths can be bronchoprotective and blunt the response, reducing sensitivity — especially in mild or well-controlled asthma.

Medication Washout (to Avoid False Negatives)

Medication ClassWashout Period
Short-acting beta-agonists (SABA)≥ 6 hours
Long-acting beta-agonists (LABA)~24 hours
Ultra-long-acting beta-agonists~48 hours
Short-acting anticholinergics (e.g., ipratropium)~12 hours
Long-acting muscarinic antagonists (LAMA, e.g., tiotropium)7 days
  • Inhaled corticosteroids, leukotriene blockers, and antihistamines do not significantly affect the test acutely — continue these. Withdrawing ICS also carries its own risk for asthma patients.
  • Practical tip: Spell out exactly what to hold and when — for both the patient and the PFT lab — at the time the test is ordered.

Interpreting Results

Negative Test (PC20 > 16 mg/mL)

  • Very high negative predictive value in symptomatic adults.
  • Makes current asthma quite unlikely (assuming proper test conduct).
  • This is the test’s greatest strength: it is an excellent rule-out test.

Positive Test (PC20 ≤ 8–16 mg/mL)

  • More nuanced — airway hyperresponsiveness is not unique to asthma.
  • Can be positive in: chronic cough, allergic rhinitis, COPD, and even some healthy asymptomatic individuals.
  • A positive result raises probability but must be interpreted alongside the clinical story, variable respiratory symptoms, peak flow variability, FeNO, and ICS response.

Safety and Risks

  • Overall, the test is quite safe; significant adverse effects are rare.
  • Temporary breathing discomfort is expected (bronchoconstriction is being induced).
  • Severe bronchospasm is possible:
    • A trained clinician should be available; SABA inhaler/nebulizer must be immediately on hand; a physician should be reachable in the facility.
  • Contraindications / cautions:
    • Avoid if FEV1 < 70% predicted or < 1–1.5 L (baseline obstruction greatly increases risk).
    • Avoid within 3 months of an acute cardiac event (rare risk of cardiac events with unstable cardiac disease).

Five Pearls — Quick Recap

  1. What it tests: Methacholine challenge is a direct test of AHR with high specificity but variable sensitivity — it belongs inside a diagnostic pathway, not as a standalone asthma test.
  2. When to use it: Most useful for symptomatic patients with normal spirometry and no bronchodilator response, after FeNO and peak flow variability have been considered.
  3. Technique and meds matter: Use tidal breathing protocol; respect washout intervals — especially the 7-day LAMA washout and 24–48 hour LABA window — to avoid false negatives.
  4. Safety: Generally safe, but can induce significant bronchoconstriction. Have a SABA available and avoid the test in patients with FEV1 < 70% predicted.
  5. Interpretation: A negative test (PC20 > 16 mg/mL) strongly argues against current asthma. A positive test raises probability but is not specific — interpret alongside the full clinical picture.
  1. Coates AL, Wanger J, Cockcroft DW, Culver BH; Bronchoprovocation Testing Task Force: Kai-Håkon Carlsen; Diamant Z, Gauvreau G, Hall GL, Hallstrand TS, Horvath I, de Jongh FHC, Joos G, Kaminsky DA, Laube BL, Leuppi JD, Sterk PJ. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017 May 1;49(5):1601526. doi: 10.1183/13993003.01526-2016. PMID: 28461290.
  2. Lee, J., & Song, J. U. (2021). Diagnostic comparison of methacholine and mannitol bronchial challenge tests for identifying bronchial hyperresponsiveness in asthma: a systematic review and meta-analysis. Journal of Asthma, 58(7), 883–891. https://doi.org/10.1080/02770903.2020.1739704
  3. Davis BE, Blais CM, Cockcroft DW. Methacholine challenge testing: comparative pharmacology. J Asthma Allergy. 2018 May 14;11:89-99. doi: 10.2147/JAA.S160607. PMID: 29785128; PMCID: PMC5957064.

117. Pulm PEEPs Pearls: Spontaneous Breathing Trials

PPP Cover Images

This week’s Pulm PEEPs Pearls episode is all about spontaneous breathing trials (SBTs). SBTs are a standard part of the daily practice in the intensive care unit, but the exact methods vary across ICUs and institutions. Listen in to hear about the most common methods of SBTs, the physiology of each method, and what the evidence says.

This episode was prepared with research by Pulm PEEPs Associate Editor George Doumat.

Dustin Latimer, another Pulm PEEPs Associate Editor, assisted with audio and video editing.

  1. What an SBT is really testing
  • An SBT is a stress test for post-extubation work of breathing, not just a ventilator check.
  • The goal is to balance sensitivity and specificity:
    • Too hard → unnecessary failures and delayed extubation
    • Too easy → false positives and higher risk of reintubation
  1. Common SBT modalities and how they compare
  • T-piece
    • No inspiratory support and no PEEP
    • Highest work of breathing
    • Most “physiologic” but often too strict
  • Pressure support (PS) + PEEP (e.g., 5/5 or 8/5)
    • Offsets ETT resistance and provides modest assistance
    • Easier to pass than T-piece
  • CPAP (0/5)
    • No inspiratory help, but provides PEEP to counter ETT resistance
    • Sits between PS and T-piece in difficulty
  1. Evidence favors pressure-supported SBTs for most patients
  • Large meta-analysis (~6,000 patients, >40 RCTs):
    • Pressure-supported SBTs increase successful extubation (~7% absolute benefit)
    • No increase in reintubation rates
  • Trials (e.g., FAST trial):
    • Patients pass SBTs earlier
    • Leads to earlier extubation and fewer ventilator-associated risks
  • Bottom line: A 30-minute PS 5/5 SBT is evidence-based and appropriate for most stable ICU patients
  1. When a T-piece still makes sense

T-piece SBTs are useful when:

  • Cost of reintubation is high
    • Difficult airway
    • Prior failed extubation
  • Pretest probability of success is low
    • Prolonged or difficult weaning
    • Tracheostomy vs extubation decisions
  • Need to mimic physiology without positive pressure
    • In LV dysfunction or pulmonary edema even small amounts PEEP may significantly improve physiology
  • Some centers use a hybrid approach: PS SBT → short confirmatory T-piece before extubation
  1. CPAP as a middle ground
  • Rationale:
    • Allows full patient effort while compensating for ETT resistance
  • Evidence:
    • Fewer and smaller trials
    • Possible modest improvement in extubation success
    • No clear mortality or LOS benefit
  • Reasonable option based on patient physiology, institutional protocols, and clinician comfort
  1. No single “perfect” SBT mode
  • Across PS, T-piece, CPAP, and newer methods (e.g., high-flow via ETT) there are no consistent differences in mortality or length of stay
  • What matters most:
    • Daily protocolized screening
    • Thoughtful bedside clinical judgment
    • Matching SBT difficulty to patient-specific risk
  1. Institutional variation is normal—and acceptable
  • Examples:
    • PS 10/5 in postoperative surgical ICU patients
    • PS 5/0 as an intermediate difficulty option
  • Key question clinicians should ask: What does passing or failing this specific SBT tell me about this patient’s likelihood of post-extubation success?
  1. Take-home pearls
  1. SBTs are stress tests of post-extubation physiology.
  2. PS 5/5 for 30 minutes is a strong default for most ICU patients.
  3. T-piece trials are valuable when false positives are costly or physiology demands it.
  4. CPAP is reasonable but supported by less robust data.
  5. Consistency, daily screening, and judgment matter more than the exact mode.

  • Burns KEA, Khan J, Phoophiboon V, Trivedi V, Gomez-Builes JC, Giammarioli B, Lewis K, Chaudhuri D, Desai K, Friedrich JO. Spontaneous Breathing Trial Techniques for Extubating Adults and Children Who Are Critically Ill: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024 Feb 5;7(2):e2356794. doi: 10.1001/jamanetworkopen.2023.56794. PMID: 38393729; PMCID: PMC10891471.
  • Burns KEA, Sadeghirad B, Ghadimi M, Khan J, Phoophiboon V, Trivedi V, Gomez Builes C, Giammarioli B, Lewis K, Chaudhuri D, Desai K, Friedrich JO. Comparative effectiveness of alternative spontaneous breathing trial techniques: a systematic review and network meta-analysis of randomized trials. Crit Care. 2024 Jun 8;28(1):194. doi: 10.1186/s13054-024-04958-4. PMID: 38849936; PMCID: PMC11162018.
  • Subirà C, Hernández G, Vázquez A, Rodríguez-García R, González-Castro A, García C, Rubio O, Ventura L, López A, de la Torre MC, Keough E, Arauzo V, Hermosa C, Sánchez C, Tizón A, Tenza E, Laborda C, Cabañes S, Lacueva V, Del Mar Fernández M, Arnau A, Fernández R. Effect of Pressure Support vs T-Piece Ventilation Strategies During Spontaneous Breathing Trials on Successful Extubation Among Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA. 2019 Jun 11;321(22):2175-2182. doi: 10.1001/jama.2019.7234. Erratum in: JAMA. 2019 Aug 20;322(7):696. doi: 10.1001/jama.2019.11119. PMID: 31184740; PMCID: PMC6563557.
  • Burns KEA, Wong J, Rizvi L, Lafreniere-Roula M, Thorpe K, Devlin JW, Cook DJ, Seely A, Dodek PM, Tanios M, Piraino T, Gouskos A, Kiedrowski KC, Kay P, Mitchell S, Merner GW, Mayette M, D’Aragon F, Lamontagne F, Rochwerg B, Turgeon A, Sia YT, Charbonney E, Aslanian P, Criner GJ, Hyzy RC, Beitler JR, Kassis EB, Kutsogiannis DJ, Meade MO, Liebler J, Iyer-Kumar S, Tsang J, Cirone R, Shanholtz C, Hill NS; Canadian Critical Care Trials Group. Frequency of Screening and Spontaneous Breathing Trial Techniques: A Randomized Clinical Trial. JAMA. 2024 Dec 3;332(21):1808-1821. doi: 10.1001/jama.2024.20631. PMID: 39382222; PMCID: PMC11581551.
  • Mahul M, Jung B, Galia F, Molinari N, de Jong A, Coisel Y, Vaschetto R, Matecki S, Chanques G, Brochard L, Jaber S. Spontaneous breathing trial and post-extubation work of breathing in morbidly obese critically ill patients. Crit Care. 2016 Oct 27;20(1):346. doi: 10.1186/s13054-016-1457-4. PMID: 27784322; PMCID: PMC5081985.
  • Yi LJ, Tian X, Chen M, Lei JM, Xiao N, Jiménez-Herrera MF. Comparative Efficacy and Safety of Four Different Spontaneous Breathing Trials for Weaning From Mechanical Ventilation: A Systematic Review and Network Meta-Analysis. Front Med (Lausanne). 2021 Nov 22;8:731196. doi: 10.3389/fmed.2021.731196. PMID: 34881255; PMCID: PMC8647911.​

114. Pulm PEEPs Pearls: Airway Clearance Techniques in Non-CF Bronchiectasis

PPP Cover Images

This week’s Pulm PEEPs Pearls episode is a focused discussion between Furf and Monty about non-pharmacologic techniques for airway clearance in the non-Cystic Fibrosis bronchiectasis population. This is a focused, high-yield discussion of the key points about airway clearance, including practical tips and a discussion of the evidence.

This episode was prepared in conjunction with George Doumat MD. Goerge is an internal medicine resident at UT Southwestern and joined us for a Pulm PEEPs – BMJ Thorax journal club episode. He is now acting as a Pulm PEEPs Editor for the Pulm PEEPs Pearls series.

1) Why airway clearance matters in non-CF bronchiectasis

  • Non-CF bronchiectasis is defined by irreversible bronchial dilation with impaired mucociliary clearance, leading to mucus retention.
  • Retained sputum drives the classic vicious cycle: mucus → infection → neutrophilic inflammation → airway damage → worse clearance.
  • Airway clearance techniques (ACTs) are meant to interrupt this cycle, primarily by improving mucus mobilization and symptom control.

2) What ACTs are trying to achieve clinically

  • Main benefits are:
    • More effective sputum clearance
    • Reduced cough/dyspnea burden
    • Improved activity tolerance and quality of life
  • Effects on spirometry are usually small.
  • Exacerbation reduction is possible, but evidence is mixed—some longer-term data suggest benefit for specific techniques.

3) The main ACT “families” and when to use them

Breathing-based techniques (device-free, flexible)

  • ACBT (Active Cycle of Breathing Technique): breath control → deep breaths with holds → huffing.
    • Pros: portable, adaptable, good first-line option.
    • Key requirement: teaching/coaching to get technique right.
  • Autogenic drainage: controlled breathing at different lung volumes to move mucus from peripheral → central airways.
    • Pros: no device, can work well once learned.
    • Cons: more technically demanding, needs training and practice.

PEP / Oscillatory PEP (stents airways + “vibrates” mucus loose)

  • PEP: back-pressure helps prevent small airway collapse during exhalation; often paired with huff/cough.
  • Oscillatory PEP (Flutter/Acapella/Aerobika): adds oscillation that many patients find easy and satisfying to use.
    • Good fit for: people who benefit from airway stenting, want something portable, and prefer a device.

Mechanical/manual techniques (help when patient can’t self-clear well)

  • HFCWO (“the vest”): external chest wall oscillation; helpful for high sputum volumes, dexterity limits, or difficulty coordinating breathing maneuvers.
  • Postural drainage/percussion/vibration: caregiver/therapist-assisted options; still useful but consider:
    • GERD/reflux risk with certain positions
    • Hemoptysis risk with vigorous techniques

4) How to choose the “right” technique (the practical framework)

There is no one-size-fits-all. Match the tool to the patient:

  • Sputum burden (volume/viscosity)
  • Strength, coordination, cognition, dexterity
  • Comorbidities (GERD, hemoptysis history, severe obstruction/airway collapse)
  • Lifestyle + portability (what they’ll actually do)
  • Cost/access and availability of respiratory therapy/physio support

A key mindset from the script: this is not a lifetime contract—reassess and adjust over time with shared decision-making.

5) Evidence takeaways (what improves, what doesn’t)

  • ACTs reliably improve sputum expectoration and often symptoms/QoL.
  • QoL/cough scores (e.g., SGRQ, LCQ) tend to improve modestly, particularly with oscillatory PEP and some vest studies.
  • Lung function: typically minimal change; occasional short-term FEV₁ benefit is reported in some vest trials.
  • Exacerbations: mixed overall; the script highlights a longer-term RCT of ELTGOL showing fewer exacerbations at 12 months vs placebo exercises.
  • Safety: generally excellent; main cautions are hemoptysis and reflux (depending on technique/positioning).

6) Special population pearls

  • Hemoptysis / fragile airways: start with gentle breathing-based ACTs (ACBT, controlled huffing); avoid overly vigorous oscillatory/manual methods if concerned.
  • Severe obstruction or early airway collapse: PEP/oscillatory PEP can help by keeping small airways open on exhalation.
  • Mobility/coordination barriers: consider HFCWO vest or simple oscillatory PEP devices to enable daily adherence.
  • During exacerbations: keep it simple—1–2 reliable techniques, prioritize daily consistency, and re-check technique.

7) The “real” bottom line

  • Start with simple, self-manageable options (often ACBT ± PEP).
  • The “best” ACT is the one the patient will do consistently.
  • Reassess technique and fit over time; education and demonstration are part of the therapy.

 Lee AL et al., “Airway clearance techniques for bronchiectasis,” Cochrane Database Syst Rev. 2015; PMC7175838. PMID: 26591003.

Athanazio RA et al., “Airway Clearance Techniques in Bronchiectasis,” Front Med (Lausanne). 2020; PMC7674976. PMID: 33251032.

Iacono R et al., “Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis,” Eur Rev Med Pharmacol Sci. 2015; PMID: 26078380.

Polverino E et al., “European Respiratory Society statement on airway clearance techniques in bronchiectasis,” Eur Respir J. 2023; PMID: 37142337.

Doumat G, Aksamit TR, Kanj AN. Bronchiectasis: A clinical review of inflammation. Respir Med. 2025 Aug;244:108179. doi: 10.1016/j.rmed.2025.108179. Epub 2025 May 25. PMID: 40425105.

111. Pulm PEEPs Pearls: Methylene Blue

PPP Cover Images (1)

Furf and Monty are back today with another Pulm PEEPs Pearls episode, and discussing the use of methylene blue for patients with septic shock. They review the clinical scenarios when this comes up, the mechanism, some key data, and some take aways, all in 15 minutes! Let us know any other topics you’d like covered on the show and make sure to like, give us 5 stars, and subscribe wherever you’re listening to this podcast.

This episode was prepared in conjunction with George Doumat MD. Goerge is an internal medicine resident at UT Southwestern and joined us for a Pulm PEEPs – BMJ Thorax journal club episode. He is now acting as a Pulm PEEPs Editor for the Pulm PEEPs Pearls series.

  1. Clinical context: when does methylene blue even come up?
  • This is not a first-line sepsis drug.
  • It’s considered in catecholamine-refractory vasoplegic septic shock, typically when:
    • Norepinephrine is at high dose
    • Vasopressin is on board
    • Often a 3rd or 4th vasopressor is being used (e.g., phenylephrine, angiotensin II)
  • The phenotype is strongly vasodilatory/vasoplegic (warm, distributive shock) rather than primarily cardiogenic.
  1. Mechanism of action (why it might help)
  • Methylene blue:
    • Inhibits inducible nitric oxide synthase and guanylate cyclase.
    • Blunts excess nitric oxide and cyclic GMP–mediated vasodilation, which are key in vasoplegic sepsis.
  • Practical translation:
    • It restores vascular tone and can make the vasculature more responsive to catecholamines.
  • It’s also used in post-CPB vasoplegia (e.g., after cardiac surgery, especially in patients on ACE inhibitors) and has migrated from that world into ICU sepsis practice.
  1. Typical dosing strategy (as described in the episode)
  • Common approach:
    • 1–3 mg/kg IV bolus, then
    • Reassess hemodynamics (MAP, dynamic perfusion markers).
    • If there’s a response, consider a continuous infusion or repeat bolus.
  • Key nuance: unlike other pressors that start as drips, methylene blue is often trialed as a bolus first to see if it’s doing anything.
  1. What does the evidence suggest?

Most data are from small, single-center, heterogeneous studies, so evidence quality is low. Meta-analyses and systematic reviews (through ~2024–25) suggest:

  • Hemodynamics
    • Can increase MAP (roughly 1–10 mmHg across studies).
    • May shorten total vasopressor duration (one meta-analysis ~30 hours less, though this is not definitive).
  • Secondary physiologic effects
    • Some small improvements in PaO₂/FiO₂ (P/F) ratio in certain studies.
  • Clinical outcomes
    • Possible reduction in hospital length of stay (≈ up to 2 days in some pooled analyses).
    • Some signal toward lower short-term mortality, but:
      • Studies are small
      • Heterogeneous
      • Evidence is very low certainty
  • Bottom line:
    • There’s a repeatable signal that methylene blue:
      • Raises MAP
      • Helps reduce catecholamine requirements
    • But hard clinical outcomes (mortality, LOS, ventilator days) remain uncertain.
  1. Safety profile & important adverse effects

Things to watch for:

  • Methemoglobinemia
  • Serotonin syndrome
    • Especially in patients on SSRIs, though in life-threatening refractory shock the hosts still lean toward using it with caution.
  • Pulse oximeter artifact
    • Can distort SpO₂ readings.
  • Urine discoloration
    • Blue/green urine—benign but striking.

Notably:

  • Methylene blue is both a treatment for and a potential cause of methemoglobinemia, depending on context and dosing.
  1. Guidelines & where it fits in practice
  • Surviving Sepsis Campaign 2021:
    • Does not recommend methylene blue for routine use in septic shock.
  • No major critical care society includes it in standard septic shock bundles or protocols.
  • The hosts frame methylene blue as:
    • A rescue therapy, not guideline therapy.
    • Something to consider only in refractory vasoplegic shock, ideally with:
      • Multidisciplinary discussion (intensivist, pharmacist, etc.).
      • Clear documentation that this is off-guideline, salvage use.
  1. Practical bedside framing (“2 a.m. in the ICU”)

They emphasize three pillars of practice:

  1. Physiology – mechanism makes sense (NO / cGMP / vasodilation).
  2. Empiric evidence – small studies and meta-analyses show a signal but low-quality data.
  3. Bedside reality – at 2 a.m., with a patient in multi-pressor, refractory vasoplegic shock, you sometimes reach for imperfect tools.

So, the practical take:

  • You should NOT:
    • Use methylene blue early.
    • Treat it as part of standard sepsis care.
  • You may consider it when:
    • Shock is clearly vasoplegic and refractory.
    • Norepi + vasopressin + at least one more vasopressor are maxed.
    • Team agrees this is salvage therapy and understands the limited evidence and side effects.

106. Pulm PEEPs Pearls: ICI Pneumonitis

PPP Cover Images (1)

We are so excited to be launching a new series here at Pulm PEEPs! We’ll be talking about high yield topics in 15 minutes or less. In this series, Furf and Monty will tackle core points and provide an overview, key points, and further reading. We’re starting with a key point review of Immune Checkpoint Inhibitor Pneumonitis. Let us know if there are other topics you want to hear about!

  1. Epidemiology & Pathophysiology
    • Increasingly common as immunotherapy use grows in oncology.
    • Caused by immune activation from PD-1, PD-L1, or CTLA-4 inhibitors.
    • Mechanisms:
      1. Overactive T cells
      2. Autoantibody production
      3. Cytokine-mediated inflammation (e.g., ↑IL-1, ↑IL-6)
  1. Clinical Suspicion & Diagnosis
    • Any new respiratory symptoms in a patient currently or previously on ICI → consider ICI pneumonitis.
    • CT findings are variable: can mimic organizing pneumonia, NSIP, ARDS, or diffuse ground glass opacities. Imaging pattern does not determine severity grade.
    • Diagnosis is of exclusion — infection and malignancy progression must be ruled out first.
    • Workup:
      • Broad infectious evaluation (cultures, viral panel, fungal markers).
      • Early bronchoscopy with BAL if feasible — typically lymphocyte-predominant in ICI pneumonitis.
      • Screen for TB and hepatitis early (in case infliximab is needed).
  1. Severity Grading (Symptom- & O₂-based, not imaging-based)
    • Grade 1: Asymptomatic → monitor, may hold ICI.
    • Grade 2: Symptomatic but not hypoxic → prednisone 1 mg/kg/day PO.
    • Grade 3–4: Hypoxemia or ICU-level care → methylprednisolone 1–2 mg/kg/day IV. Usually hold or permanently stop ICI.
  1. Steroid Management
    • Typical taper: over 6 weeks for grade ≥3.
      • Week 1: 1–2 mg/kg/day
      • Gradual step-down to 0.25 mg/kg/day by week 5, then stop week 6.
    • Chronic/recurrent cases may need slower tapers over months.
    • Add GI prophylaxis and PJP prophylaxis during prolonged steroid use.
  1. If Steroids Fail (no improvement after 48–72 hrs)
    • Consider adding:
      • IVIG (2 g/kg over 5 days)
      • Infliximab (TNF-α inhibitor — requires TB/hepatitis screening)
      • Mycophenolate mofetil (1–1.5 g/day BID or TID, start at effective dose quickly)
    • IVIG may have lower mortality in some series but comes with risks (volume overload, thrombosis, infusion reactions).
  1. Emerging Therapies
    • JAK inhibitors are under investigation as possible future options.
  1. Multidisciplinary Care
    • ICU management is a team sport — coordinate with oncology, critical care, infectious disease, and pharmacy.

 

 

  1. Managing Immune Checkpoint Inhibitor Pneumonitis in the ICU. Montemayor, Kristina et al.CHEST Critical Care, Volume 3, Issue 1, 100126
  2. Lavalle S, Masiello E, Valerio MR, Aliprandi A, Scandurra G, Gebbia V, Sambataro D. Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review). Exp Ther Med. 2024 Jul 30;28(4):381. doi: 10.3892/etm.2024.12670. PMID: 39113908; PMCID: PMC11304171.
  3. Delaunay M, Prévot G, Collot S, Guilleminault L, Didier A, Mazières J. Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur Respir Rev. 2019 Nov 6;28(154):190012. doi: 10.1183/16000617.0012-2019. PMID: 31694838; PMCID: PMC9488507.

95. Clinical Pearl: Prone Positioning with Elevated Intracranial Pressure

Case Files

Today we have a mini-episode / clinical pearl. We previously discussed the PROSEVA trial and the evidence for prone positioning in ARDS. In that trial, patients with elevated intracranial pressure (ICP) were excluded. We are joined now by Dr. Jon Rosenberg, a neuro intensivist, to discuss his how prone positioning can still be employed for patients with neurologic injuries and elevated ICP.

 

Dr. Jon Rosenberg is an assistant professor of neurology and neurosurgery at Westchester Medical Center, New York Medical College. He’s also the associate program director of the Neurocritical Care Fellowship at Westchester Medical Center and a frequent contributor to the Neurocritical Care Society podcast.

 

  1. Elevated Intracranial Pressure (ICP) and Proning: A Common Misconception
  • Elevated ICP is often considered a contraindication to proning, but this is more of a relative caution rather than an absolute contraindication.
  • Many neuro ICUs have successfully proned patients with elevated ICP, particularly since the COVID-19 pandemic, when critical care units had to manage both respiratory failure and neurological conditions simultaneously.
  1. Patient Selection for Proning with Elevated ICP
  • Most patients with elevated ICP can still be proned, including those with:
    • Global cerebral edema (e.g., post-anoxic brain injury, liver failure)
    • Focal lesions (e.g., traumatic brain injury, large ischemic strokes, intracerebral hemorrhage)
  • Situations where proning might be more concerning:
    • Severe hemodynamic instability (multi-pressor shock)
    • Morbid obesity (e.g., >300 lbs), where physically flipping the patient is a major challenge
  1. Theoretical Concerns with Proning in Elevated ICP
  • Loss of neurological exam access (sedation + flipped position makes pupil and motor exam difficult)
  • Jugular venous compression (especially if the head is turned to one side)
  • Cerebrospinal fluid (CSF) flow obstruction, depending on the lesion
  • Risk of increased ICP if venous outflow is impaired or head positioning is not optimized
  1. Best Practices for Proning Patients with Elevated ICP
  • Patients with invasive ICP monitors vs. without monitors:
    • If possible, placing an ICP monitor (EVD or parenchymal bolt) before proning provides better guidance.
    • Without a monitor, providers must rely on other practices like maintaining strict MAP goals and sodium targets, and indirect signs of increased ICP.
  • Positioning considerations:
    • Keep the head midline to prevent jugular venous compression.
    • If head positioning is not neutral, place the dominant/internal jugular facing upward to maintain venous drainage.
    • Maintain the head of the bed elevated even while prone (reverse Trendelenburg positioning).
  • Hemodynamic management:
    • Target a higher MAP (e.g., 70–75 mmHg, sometimes 75–80 mmHg) to ensure adequate cerebral perfusion pressure (CPP) if there is no ICP monitor
    • Avoid hypotension, as MAP – ICP = CPP, and low MAP could critically reduce cerebral perfusion.
      • A normal intracranial pressure is 7 – 15 mmHg
      • The recommended CPP is between 60 – 70 mmHg
  • Sedation & Sodium Management:
    • Consider deep sedation (RASS -5) to reduce metabolic demand and intracranial blood volume.
    • Consider keeping sodium >145 mmol/L prophylactically to mitigate brain swelling if no ICP monitor in place
  1. When to Reconsider Proning (i.e. when to supinate)
  • If a patient’s ICP spikes significantly (e.g., from 20 to 60 mmHg) despite medical management (hypertonic saline, sedation, paralysis, etc.).
  • If new signs of neurological deterioration emerge (e.g., changes in pupil exam once patient is repositioned).
  • Hemodynamic instability that is unmanageable in the prone position.
  1. Literature and Future Considerations
  • Small case series have demonstrated success in proning patients with traumatic brain injury (TBI) and aneurysmal subarachnoid hemorrhage.
  • While more formal research is needed, the neurocritical care community has begun embracing proning for neuro patients, provided that proper precautions are taken.

Bottom Line

  • Proning is not an absolute contraindication for patients with elevated ICP—it can be done safely with proper monitoring, patient selection, and precautions.
  • Having an ICP monitor makes the process more controlled and allows clinicians to adjust treatment in real time.
  • Key considerations: Maintain cerebral perfusion, optimize head positioning, monitor hemodynamics, and have a plan for reversing if ICP becomes unmanageable.